Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging.
Level 2 - randomized trial
Randomized clinical trial with 12-year follow-up
PubMed 17426848 · doi:10.1007/s10517-006-0365-z
What was done
A 12-year randomized clinical study evaluated long-term epithalamine (a pineal gland peptide preparation) treatment alongside standard therapy compared to standard therapy alone in elderly patients with coronary disease and accelerated cardiovascular aging. Specific dosing schedules, blinding methods, and cohort sizes were not reported in the abstract.
What was found
Over 12 years of follow-up, the epithalamine-treated group exhibited: - 28% lower all-cause mortality compared to the control group. - 2-fold lower cardiovascular mortality. - 2-fold lower incidence of cardiovascular failure and respiratory diseases. - Decreased functional age, decreased degree of cardiovascular aging, and increased exercise tolerance (no baseline values, absolute event counts, or p-values reported).
Why it matters
This study reports that long-term pineal peptide therapy may significantly lower mortality and cardiovascular morbidity in elderly patients with cardiovascular disease.
Limits
The abstract reports no sample size, dropout rates, confidence intervals, or p-values. It also lacks details regarding randomization procedures, blinding, control group composition, and exact drug administration protocols.
Cited by
- context A 15-year study by Khavinson administering Epithalamin and Thymalin to nursing home patients showed significant reductions in cardiovascular, infectious, and cancer mortality.